A detailed history of Clearstead Advisors, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Clearstead Advisors, LLC holds 481 shares of REGN stock, worth $337,589. This represents 0.01% of its overall portfolio holdings.

Number of Shares
481
Previous 504 4.56%
Holding current value
$337,589
Previous $529,000 4.54%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1024.09 - $1201.76 $23,554 - $27,640
-23 Reduced 4.56%
481 $505,000
Q2 2024

Aug 09, 2024

BUY
$883.2 - $1071.19 $62,707 - $76,054
71 Added 16.4%
504 $529,000
Q1 2024

May 14, 2024

SELL
$902.69 - $993.35 $41,523 - $45,694
-46 Reduced 9.6%
433 $416,000
Q4 2023

Feb 12, 2024

BUY
$775.18 - $881.7 $13,178 - $14,988
17 Added 3.68%
479 $420,000
Q3 2023

Nov 07, 2023

SELL
$692.45 - $844.37 $11,771 - $14,354
-17 Reduced 3.55%
462 $380,000
Q2 2023

Aug 07, 2023

BUY
$700.03 - $830.35 $17,500 - $20,758
25 Added 5.51%
479 $344,000
Q1 2023

May 09, 2023

BUY
$680.49 - $826.97 $87,102 - $105,852
128 Added 39.26%
454 $373,000
Q4 2022

Feb 14, 2023

BUY
$705.89 - $766.39 $19,059 - $20,692
27 Added 9.03%
326 $235,000
Q4 2021

Feb 14, 2022

BUY
$543.48 - $670.97 $117,935 - $145,600
217 Added 264.63%
299 $189,000
Q2 2021

Aug 12, 2021

SELL
$472.8 - $558.54 $10,401 - $12,287
-22 Reduced 21.15%
82 $46,000
Q1 2021

May 14, 2021

BUY
$446.73 - $548.2 $15,635 - $19,187
35 Added 50.72%
104 $49,000
Q4 2020

Feb 11, 2021

BUY
$478.3 - $607.98 $956 - $1,215
2 Added 2.99%
69 $33,000
Q3 2020

Nov 12, 2020

BUY
$544.75 - $658.21 $8,171 - $9,873
15 Added 28.85%
67 $38,000
Q1 2020

May 14, 2020

BUY
$336.18 - $494.43 $17,481 - $25,710
52 New
52 $25,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $75.2B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Clearstead Advisors, LLC Portfolio

Follow Clearstead Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clearstead Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clearstead Advisors, LLC with notifications on news.